You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201341 - 201350 of 205243 results
  1. Modular Ultrasonic Beacon System (MUBS) for Ultrasound-guided Interventional Surg

    SBC: Nymirum, Inc.            Topic: NIAMS

    DESCRIPTION: Myotonic dystrophy 1 (DM1) is the leading form of adult muscular dystrophy resulting in progressive neuromuscular effects. The disease affects 1 in 6000 people. Nymirum is interested in identifying a small molecule that can be used to slow oreliminate the progression of DM1. The cause of DM1 is the expansion of a CUG RNA sequence within the DMPK gene. This repeat RNA is toxic to no ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Broadly protective (universal) virus-like particle (VLP) based influenza vaccine

    SBC: ALGOMEDIX, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): A safe and effective therapeutic for treatment of osteoarthritis (OA) represents a major unmet medical need. OA is the leading cause of disability in the US and pain is a predominant clinical feature. However, chronicuse of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with potentially life-threatening gastrointestinal bleeding and calculations ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Design of an Interactive Incentive Spirometer for Enhanced Respiratory Care

    SBC: AMBRYX BIOTECHNOLOGY, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Cancer and rheumatoid arthritis (RA) share remarkably similar pathogenic pathways. For example, in both cancer and RA, angiogenesis, chronic inflammation and reactive oxygen species create a negative feedback loop thataccelerates disease progression. In the synovium of RA patients, fibroblast-like synoviocytes (RA- FLS) has features of tumor-like transformation ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Administrative supplement to 5R44DA025375-03: Prescription drug abuse prevention

    SBC: WELLGEN, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Type 2 Diabetes (T2D) is an inflammatory disease affecting 26 million people in the US (11%) and is predicted to affect more than 30% of adults in the US by 2050. The economic cost of T2D is over 200 billion a year. People with T2D suffer from hyperglycemia due to low insulin production, poor transport of insulin, or cellular resistance to insulin which can l ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Automated Sample Preparation for Next Generation Sequencing Cancer Diagnostics

    SBC: ADVANCED LIQUID LOGIC            Topic: NCI

    DESCRIPTION (provided by applicant): As more diverse genetic links are established with cancer, the utility of one-gene-one-test diagnostics is diminished. In addition, biopsies are mixed populations of tumor and normal tissue, requiring deconvolution oftumor and non-tumor genoptypes to accurately understand disease etiology and inform treatment decisions. The next generation of cancer diagnostic ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Novel VLP Adjuvant based on the VesiVax system

    SBC: Euclid Diagnostics LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Over one million prostate biopsies are performed in the US each year to diagnose approximately 200,000 cases of prostate cancer. The majority of these biopsies are performed needlessly. The overall objective of this project is to develop a secondary prostate cancer diagnostic test that can be performed on men with elevated PSA in order to identify patients in n ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Biodegradable Drug-Eluting Surgical Meshes with Tunable Release Kinetics

    SBC: ACUITYBIO CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): We have developed and are optimizing a prototype drug-eluting surgical mesh comprised of novel copolymer blends for controlled locoregional delivery of chemotherapy to prevent local colorectal tumor recurrence following surgical resection. Colorectal cancers are the third largest cancer killer in the US with the identificationof an estimated new 40,000 rectal ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Osteosarcoma in Dogs as a Model for the Development of Drugs to Treat Micro-metas

    SBC: CYPRIS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This project will determine the efficacy of tetrathiomolybdate (TM), a potent copper- reducing compound to effectively inhibit angiogenesis and disrupt fatal micro-metastatic progression to vital organs common in humancancers. To evaluate TM's capacity in this role, a clinical trial will be conducted on dogs diagnosed with osteosarcoma (OS) of the leg bone ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Vitamin B6 based prodrugs of gemcitabine

    SBC: MBC Pharma, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form that enables increased pathways for uptake into cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling

    SBC: ADAPTIVE BIOTECHNOLOGIES CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling T-cell neoplasms are generally more aggressive and have poorer outcomes than comparable B-cell lymphomas. In addition, for many of these patients, prognosis following disease relapse is dismal. Detecting the presence or absence of Minimal Residual Disease (MRD) following treatment is em ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government